Abstract
As millions of glaucoma patients lose sight, it has become accepted that there is a need to develop neuroprotective therapies that can be used, in conjunction with hypotensive drugs, to prevent retinal ganglion cell (RGC) death. Recent advances in the understanding of the pathophysiology of glaucoma make it evident that local ischemia and perfusion abnormalities are a key factor in the pa…